Navigation Links
Ambrx to Present Phase I/II Clinical Data for Optimized, Long Acting Human Growth Hormone Analogue
Date:11/5/2008

SAN DIEGO, Nov. 5 /PRNewswire/ -- Ambrx Inc. today announced the scheduled presentation of data from a Phase I/II clinical trial of ARX201, the company's long-acting human growth hormone (hGH) analogue developed in collaboration with Merck Serono, at the International Congress of Endocrinology meeting in Rio de Janeiro. Andrew R. Hoffman, M.D., Professor of Medicine and Vice President of Academic Affairs at Stanford University, will present the clinical results as part of an oral presentation at 9:30 AM local time (GMT -3 / 7:30 AM EST) on November 12, 2008.

The Phase I/II dose-finding study in adult patients with growth hormone deficiency investigated the safety, tolerability, pharmacokinetic and pharmacodynamic profile of ARX201 following single-dose escalation and repeated dosing. The study analyzed 22 individuals with adult growth hormone deficiency (AGHD). The patients had not received hGH replacement therapy in the six months prior to the study.

ARX201 was administered once weekly by subcutaneous injection. Dosing was titrated based on IGF-I response and/or safety findings. Patients were treated for up to 26 weeks. Clinical measures of body composition were taken at the end of the study period.

About ARX201

ARX201 is a long-acting recombinant human growth hormone drug candidate currently developed by Ambrx and Merck Serono for the treatment of growth hormone deficiencies. ARX201 was generated through a lead optimization process using Ambrx's ReCODE(TM) technology, which effectively enables protein medicinal chemistry. Through this approach, Ambrx was able to generate site specific mono-pegylated hGH molecules that were optimized for potency and time of action. Ambrx believes that ARX201 may have improved pharmacological performance over existing growth hormone products, including the potential for less frequent dosing.

In pre-clinical studies, ARX201 met or exceeded key end points in assays that are believed to be pred
'/>"/>

SOURCE Ambrx Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ambrx Appoints Douglas Axelrod Senior Vice President for Clinical Research and Development
2. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
3. Avicena Group to Present at Noble Financial Conference
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
6. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
7. CEL-SCI to Present at the Noble Financial Conference
8. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
9. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
10. Strategic Diagnostics Updates Roth Conference Presentation Time
11. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... SPRINGS, Florida , September 19, 2014 ... companies release latest developments, patents and results of studies ... GNSZ), Eli Lilly and Company (NYSE: LLY ... Celgene Corporation (NASDAQ: CELG ) and Arena ... GNSZ), a leader in developing prodrug therapeutics for the ...
(Date:9/19/2014)... 2014 , The first grants ... Paediatric Endocrinology (ESPE) Meeting  Investment supports innovative ... in the field of growth  , EMD ... Germany , today announced the first recipients of ... awards were announced during a Satellite Symposium organized by ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... near-patient testing, is performed outside a clinical laboratory. ... hence in administrating appropriate treatments and medication. POCT ... and prevalence of lifestyle diseases such as diabetes, ... and user-friendly. POCT devices are standardized to minimize ...
(Date:9/18/2014)... DUBLIN, Ireland , September 18, ... ,Research and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) ... "Biocompatible Materials - Global Strategic ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report ... Materials in US$ Million by the ...
Breaking Biology Technology:Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3
... , , CLEVELAND, Sept. 9 ... for ways to drive out costs and inefficiencies. Because it,s proven ... documents that go along with them, many are turning to enterprise ... the roadblock: budgets are tighter than ever, so how do these ...
... , , THE WOODLANDS, Texas, Sept. ... LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments ... Ph.D. , Lexicon,s president and chief executive officer, will present at ... in New York, New York on Tuesday, September 15, 2009 at 1:35 ...
... BRIDGEWATER, England, September 9 Clinical Therapeutics,(, http://www.clinicaltherapeutics.com/ ... announce the addition of Michael G. Spigarelli, MD, ... As section editor for the Pediatric, ... the,Pediatric Research section), Dr. Spigarelli brings a wealth ...
Cached Biology Technology:Hyland Software Provides Grant Assistance to Kick-Start Technology Projects 2Hyland Software Provides Grant Assistance to Kick-Start Technology Projects 3Hyland Software Provides Grant Assistance to Kick-Start Technology Projects 4Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section 2
(Date:9/19/2014)... species which over thousands of years has adapted to the ... that makes the cold dangerous for you. , This is ... and the cold provoking substance, called nonylphenol, comes from the ... suspected of being a endocrine disruptor, but when entering the ... ability to protect the cells in its body from cold ...
(Date:9/18/2014)... Boulder, Colo., USA A new GSA Bulletin ... along the lower Rio Puerco and Chaco Wash in ... tree rings from salt cedar and willow, investigators were ... thick or greater. They then combined this data with ... reconstruct the history of these arroyos. , Arroyos are ...
(Date:9/18/2014)... A novel robotic system that can operate inside the ... as part of a biomedical research partnership program at ... of determining if the robot, in conjunction with real-time ... accurate, less costly, and less discomforting for the patient. ... prostate cancer therapies with greater precision. , Developed by ...
Breaking Biology News(10 mins):Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5
... the Sundarbans, resulting in as much as 200m of coast ... (11th Jan) in Remote Sensing by scientists from ... development thrives, and global temperature continues to rise, natural protection ... rates. This will inevitably lead to species loss in this ...
... W. Finberg, MD, the Richard M. Haidack Professor of ... University of Massachusetts Medical School, is lead investigator on ... predicting how the influenza virus changes and evolves in ... This approach has promise for becoming a pivotal tool ...
... cells can be grown on biocompatible scaffolds to form ... repair and regeneration of damaged or diseased tissue. However, ... a specific pattern or alignment. An innovative method for ... tissue architectures is described in an article in ...
Cached Biology News:Bengali forests are fading away 2
...
Human Presenilin-2 NTF Affinity Purified Polyclonal Ab...
2'-Fluorine-CTP (2'-F-CTP) is readily incorporated into transcripts by T7 and SP6 R&DNA™ Polymerase and is available separately....
Human Glypican 2 Biotinylated Affinity Purified PAb...
Biology Products: